- Report
- February 2024
- 150 Pages
Global
From €4084EUR$4,250USD£3,491GBP
- Report
- May 2020
- 194 Pages
Global
From €1912EUR$1,990USD£1,635GBP
- Report
- July 2019
Global
From €961EUR$1,000USD£821GBP
- Report
- April 2023
- 125 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Report
- January 2018
- 618 Pages
Global
From €21139EUR$22,000USD£18,072GBP
Mavyret is a market of drugs used to treat liver and kidney disorders. It includes medications that are used to treat chronic hepatitis C, a viral infection of the liver, as well as drugs used to treat chronic kidney disease. These drugs are used to reduce inflammation, improve liver and kidney function, and reduce the risk of complications from the diseases. Mavyret drugs are typically prescribed by a doctor and are available in both oral and injectable forms.
The Mavyret market is highly competitive, with many companies offering different types of drugs. Some of the major players in the market include AbbVie, Gilead Sciences, Merck, and Bristol-Myers Squibb. Other companies in the market include Novartis, Pfizer, and AstraZeneca. Show Less Read more
